ISS P-002

A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

Trial Details:

I Completed
Istituto Superiore di Sanita, Novartis Vaccines September 01, 2011
Tat vaccine,HIV-1 delta-V2 Env vaccine Protein Tat; Protein Env
Tat vaccine Protein
HIV-1 delta-V2 Env vaccine Protein
Italy 50